

White Paper

Evolving Landscape of Immuno-Oncology

ANJU GOPAN, Oncology/Hematology, Medical Director, IQVIA
DEAN MARVIN PIZARRO, Oncology/Hematology, Associate Medical Director, IQVIA
JAIME ENRIQUE HILADO, Oncology/Hematology, Associate Medical Director, IQVIA
MARIA ROSELLE VILLAR LUCAS, Oncology/Hematology, Senior Medical Director, Head Asia, IQVIA
JOSE LUIS GARCIA, Senior Medical Strategy Director, Oncology Center of Excellence, IQVIA
CHARU MANAKTALA, Senior Director and Head, Biosimiliars Center of Excellence, IQVIA



Table of contents

Evolving landscape of Immuno-Oncology — India perspective	1
Evolving landscape of Immuno-Oncology — global perspective	2
The progress of CAR T-cell therapy in India	4
Opportunities for Biosimilars competition at the end of the decade	5
Present challenges for Rare Cancers in India	6
Conclusion	7
Key opinion leaders	8
Acknowledgements	8
References	9
About the authors	11

Evolving landscape of Immuno-Oncology — India perspective

The incidence of cancer cases in India is expected to increase by 12.8% by 2025, highlighting a pressing need for advancements in oncology management. Lung and breast cancers are the most common among both sexes, with one in nine individuals likely to develop cancer in their lifetime. Addressing this health crisis demands innovative and effective solutions. The unmet needs in diagnostic and treatment strategies evolve in parallel with oncology advances. Oncologists now face increasingly complex decisions, balancing newly approved treatments with investigational agents. Ongoing clinical trials underscore a rise in immunotherapy approvals for early-stage cancers. The future of cancer immunotherapy hinges on combination therapies, such as immune checkpoint inhibitors (ICIs) paired with other checkpoint inhibitors, with chemotherapy, targeted therapy, and Tumor Infiltrating Lymphocytes (TIL), cell therapy like chimeric adoptive antigen receptor (CAR)-engineered immune cells — all FDA approved.

Incorporating India into these global trials could broaden patient access to these emerging therapies. Yet, achieving a universal approach presents challenges due to diverse immune-escape mechanisms. Furthermore, the high costs of these novel treatments restrict accessibility within India. To ensure that Indian patients have access to the latest treatment options, India is making significant strides in aligning its healthcare infrastructure and clinical practices with global standards. This progress includes enhancing the availability of novel treatments and facilitating access to cutting-edge clinical trials.

To understand oncologists' perspectives on crucial clinical questions and to narrow the disparity in cancer care between India and other countries, IQVIA Asia's Oncology division organized an advisory board meeting in Mumbai on November 24, 2023. The board consisted of six prominent oncologists from diverse regions of India, in conjunction with IQVIA's medical advisors from its Oncology and BIosimilar Center of Excellence (COE). This advisory board played a pivotal role in identifying the latest treatment opportunities in India, given the country's large population and increasing incidence of cancer.

The advisory board evaluated emerging treatments for various oncology indications, including combination therapies and biomarker-driven approaches. It also examined the future of Immuno-Oncology (IO) therapies with the goal of enhancing patient support through clinical trials and ensuring the availability of treatments aligns with global standards. This includes incorporating patient perspectives via standard-ofcare (SOC) questionnaires to understand the real-world impact of drugs.

With the increasing number of cancer patients, particularly those with solid tumors, there is a growing need for more clinical trials and access to the latest treatments. To achieve this, it is crucial to inform stakeholders about the strengths of India's healthcare system, medical expertise, and advancements in clinical trials and regulations. Clinical cancer research must align more closely with the country's healthcare needs and burden of disease, focusing on common and lethal cancers, as well as making clinical trials accessible across all regions and to underserved communities.


In this white paper, we will explore the evolving landscape of immuno-oncology from both global and India's perspectives. We will delve into the significant progress of CAR T-cell therapy in India, examining the development and manufacturing challenges faced and the promising results from recent clinical trials. We will also cover the opportunities of biosimilars trials and their potential to improve healthcare in India. Furthermore, we will address the present challenges for rare cancers in India, highlighting the unique epidemiology and the urgent need for innovative research models and funding to tackle these uncommon yet devastating diseases. By addressing these topics, we aim to provide a comprehensive understanding of the current landscape and prospects of immuno-oncology in India, emphasizing the importance of collaboration and innovation in improving cancer care for patients across the country.

Evolving landscape of Immuno-Oncology — global perspective

We are currently in an era of expanding oncology treatments, with immunotherapy prominently featured as a transformative approach. Immunotherapy, including vaccine therapy, CAR T cell therapy, TILs and ICIs, significantly improves cancer survival rates and is increasingly utilized across various cancer stages, particularly in early-stage tumors. According to IQVIA's analysis of published data, immunotherapy delays disease progression, enhances overall patient survival rates, and improves quality of life. Between 2018 and 2021, the application of immunotherapy expanded to include 17 additional cancer types, with non-small cell lung cancer (NSCLC) being the most prevalent. It is also being integrated with other therapies, such as in the treatment of hepatocellular carcinoma. Additionally, combining immunotherapy with other treatments such as poly adenosine diphosphate-ribose polymerase (PARP) inhibitors represents a growing area of research and practice, particularly in improving outcomes for cancers affecting women, enhancing patient survival rates and prognostic outcomes.

However, access to these drugs varies globally due to cost and reimbursement policies, with a noticeable correlation between a country's income level and the adoption of immunotherapy. Despite high costs, expanding market competition is expected to improve future accessibility as pharmaceutical companies invest more in clinical trials. This competitive landscape can potentially drive down costs and broaden the range of treatment options beyond earlier approved programmed cell death ligand (PD-(L)1) inhibitors.





Source: IQVIA European Thought Leadership, MIDAS Sales by Disease MAT Q3 2018 - 2021, PD-(L)1 inhibitors: Keytruda, Opdivo, Imfinzi, Bavencio, Tecentriq, Libtayo, Jemperli; Copyright © 2022 IQVIA. All rights reserved

In recent years, the average number of patients per clinical trial has decreased, even as the overall number of trials has increased and drug approvals have accelerated with smaller participant cohorts. This trend carries significant implications for stimulating market competition and advancing clinical research. Globally, there is a growing shift of clinical trials away from the United States of America (USA), with India emerging as a competitive destination due to its robust network of referral sites.

Moreover, there is a notable increase in single-country trials, particularly focused on PD-(L)1 agents. This trend presents both challenges and opportunities for enhancing global clinical trial diversity. Precision medicine is advancing through strides in biomarker research and next-generation sequencing (NGS). However, hurdles such as the need for improved modeling tools and more effective matching algorithms persist.

India possesses the capability for biomarker testing and advanced diagnostic modalities, yet cost remains a significant barrier for patients across diverse geographic regions.




The progress of CAR T-cell therapy in India

The development of CAR T-cell therapy in India marks a significant milestone where future trials could be conducted with clearer guidelines and reduced barriers. Pioneers in CAR T-cell therapy discussed development and manufacturing challenges in India, emphasizing the critical need for sourcing patient cells and ensuring good manufacturing practices (GMP)grade vector production. India has immense potential in Pediatric Trials. For example, The CAR T trial was a Pediatric trial and it is an unaddressed need.

In a phase I/Ib trial conducted by an expert team with twelve subjects, nine underwent infusion after multiple prior treatments. The results at day 30 showed a 66.6% complete response rate without minimal residual disease (MRD), a 25% complete response rate with MRD, and an overall response rate of 92%. Reported toxicities included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hypogammaglobulinemia. The discussion emphasized the need to increase the accessibility and affordability of CAR T-cell therapy in India. This can be achieved through local development, participation in global trials, and leveraging existing expertise and infrastructure.

The advisory board endorsed India's potential in conducting trials involving tumor infiltrating lymphocytes (TILs), highlighting the country's substantial patient pool, oncology expertise, and regulatory alignment. Confidence in India's capability to conduct Phase I trials, focusing on anti-tumor activity and targeted patient cohorts, has grown. Initiatives like the Network of Oncology Clinical Trials in India (NOCI), supported by the Biotechnology Industry Research Assistance Council of India (BIRAC), aim to enhance capacity, establish a multicentric registry, and prepare clinical trial sites nationwide.

Insights from the COVID-19 pandemic were also discussed, underscoring its transformative impact on global clinical trials. Key takeaways include the necessity of integrating remote monitoring and risk management strategies into research study protocols worldwide.



Opportunities for Biosimilars competition at the end of the decade

The lead medical advisor of IQVIA Biosimilars COE initiated a discussion on the current landscape of biosimilars, their future prospects, and anticipated challenges. Legislative amendments establishing a regulatory framework for biosimilars were enacted two decades ago. Since then, biosimilars for over 20 biological medicines have been approved and launched in international markets, significantly expanding access to treatments and reducing healthcare costs. With the extensive knowledge acquired in the development and evaluation of biosimilars, there has been an active discussion about refining clinical development processes, particularly customizing efficacy and safety study requirements based on the specific characteristics of the reference biologic and proposed biosimilar product.

Several biologic drugs, including seven cancer treatments with annual global revenues exceeding

\$1 billion (such as Keytruda[®], Opdivo[®], and Tecentriq[®]), are expected to have their patents expire by 2030. As a result, it is anticipated that within the next four to five years, more than forty international clinical trials will be launched by various entities to introduce biosimilars for these cancer treatments into the market.

Under existing regulatory guidelines, biosimilars must demonstrate comparable pharmacokinetics (PK) and pharmacodynamics (PD), as well as effectiveness, safety, and immunogenicity through extensive comparative clinical trials involving 500 participants or more. For most biosimilars, clinical PK equivalence is evaluated in healthy volunteers to mitigate variability introduced by disease and concurrent medications. However, for biosimilars of immune checkpoint inhibitors (ICIs), PK equivalence must be determined in patients due to the potential for severe immunemediated side effects affecting any organ or tissue. The anticipated increase in biosimilar and novel product trials, alongside the requirement to assess PK equivalence in patients, complicates the upcoming studies for ICI biosimilars.




Chart 2: Biosimilars pipeline 2022 — 2030: Biologics with Global Sales >1 Bn USD only

Chart: Several biologics with global revenues exceeding \$1 billion are expected to lose patent protection by 2030, potentially paving the way for biosimilars to enter the market for cancer treatments.

Despite these challenges and competitive pressures, ICI biosimilar trials present a valuable opportunity for patients in regions with limited or no access to these medications. Participants in these trials receive standard care throughout the study and can continue treatment for an additional year post-study. Moreover, these trials typically compare the biosimilar candidate directly against the reference biologic, ensuring all patients receive active treatment and are not assigned to a placebo group. Before entering clinical trials, biosimilar candidates undergo rigorous physicochemical and biological activity assays against their reference biologics. These evaluations confirm the biosimilars' identity, structure, and biological activity are sufficiently similar, providing confidence in their quality and minimizing risks to participants.

It is crucial for potential investigators and ethics committees to understand established regulatory standards for biosimilar quality and preclinical evaluation. In countries like India, the anticipated increase in ICI biosimilar trials in the coming years offers significant opportunities for local patients to access standard-of-care treatments with minimal risk.

Present challenges for Rare Cancers in India

The epidemiology of rare cancers in India differs significantly from that in other countries. Unlike the USA, where prevalent cancers listed among the top 19 include those like breast and prostate cancers, India sees higher incidences of cancers affecting the head and neck, cervix, gallbladder, and bile duct. Conversely, melanomas and other non-melanoma skin cancers are less common in India. In contrast, cancers considered rare in the USA, such as adenocarcinomas of the esophagus and stomach, squamous cell carcinoma of the esophagus and head and neck, cervical carcinoma, and Hodgkin lymphoma, are relatively more frequent in India.

Advancements in targeted therapies offer significant opportunities for improving the management of rare cancers. However, several challenges persist in rare

cancer research, including conducting clinical trials with small patient populations, adopting innovative trial methods, and securing adequate research funding. Additionally, comprehensive data on the histology of rare cancers is essential. The unique epidemiology of rare cancers in India and other South Asian Association for Regional Cooperation (SAARC) countries underscores the need for distinct recognition of these cancers in the region. This recognition should be based on realistic definitions and thresholds. emphasizing the importance of tailored approaches in diagnosis, treatment, and research initiatives. Molecular technologies and new research models are exploring the genetic profiles of various rare cancers and seeking actionable mutations. The use of checkpoint inhibitors, immunotherapy, and targeted therapies is expanding across different cancer types. In the context of India, it is essential to establish a national consortium focused on tackling rare cancers. The primary objective of this consortium would be to meticulously document the incidence of rare cancer. This data collection would be pivotal in defining rare cancers, assessing the disease's burden, categorizing rare cancers specific to India, and planning for future challenges. Well-structured clinical trials are also a crucial path ahead in cancer research, thus the International Rare Cancers Initiative will act as a crucial platform for initiating new international clinical trials targeting rare tumors that India might consider as it seeks to become part of the worldwide clinical trial landscape.



Conclusion

- 1. India faces significant challenges in cancer with a high annual diagnosis rate, thus requiring more treatment options, support, and clinical trials.
- 2. The immunotherapy market is expanding rapidly due to increased clinical trials and pharmaceutical interest. As competition grows, costs are decreasing, leading to a wider range of treatment options beyond PD-(L)1 blockers.
- 3. Current oncology research focuses on solid tumors and advanced biotherapeutic approaches. Inclusion of a country in clinical trials depends on research quality, efficiency, and availability of the patient population.
- 4. Enhancing accessibility and affordability of CAR T-cell therapy in India is crucial. This involves promoting local manufacturing, participating in global and regional research, and leveraging existing knowledge and infrastructure.
- 5. The COVID-19 pandemic has significantly reshaped global clinical trial conduct. Lessons learned underscore the value of virtual or decentralized monitoring and risk reduction strategies now integrated into research protocols.
- 6. Over the next four to five years, more than forty global clinical trials are projected to launch to support the approval of potential biosimilars for established anticancer biologics.
- 7. Aspiring researchers and ethics boards must understand regulatory standards for biosimilar integrity and preclinical assessments. The anticipated increase in ICI biosimilar studies in India presents an opportunity for local patients to access standard treatments with low risk.
- Precision medicine advancements offer substantial potential for improving rare cancer treatment. Research challenges include conducting studies with limited patient numbers, adopting novel methodologies, and securing funding.
- 9. The unique epidemiology of rare cancers in India and the SAARC region underscores the need for a customized approach to identify these cancers. Establishing a network and consortium for data collection could enhance global and regional clinical trials and treatments.
- 10. The advisory board unanimously agreed on promising future prospects for India, contingent upon resolving identified issues. Collaboration among oncology professionals and stakeholders in the public and private sectors is essential to increase patient access to the latest diagnostic and treatment options in India.

Key opinion leaders

DR. KRISHNAKUMAR RATHNAM, Consultant Medical Oncologist and HOD, Medical Oncology at Meenakshi Mission Hospital and Research Center, Madurai, India

DR. (SURG CDR) GAURAV NARULA, Professor of Pediatric Oncology & Health Sciences, Project Lead of CAR T Cell Therapy Center, and Past Convener of the Pediatric Hematolymphoid Group, Tata Medical Center, Homi Bhabha National Institute, Mumbai, India

DR. JOYDEEP GHOSH, Consultant Medical Oncologist, Tata Medical Center, Calcutta, India

DR. PRAVEEN KUMAR SHENOY VP, Associate Professor, Department of Clinical Hematology and Medical Oncology, Malabar Cancer Center, Kannur, Kerala, India

DR. ARUN SANKAR, Additional Professor in Oncology, Regional Cancer Centre, TVM, Kerala, India

DR. NIRMAL RAUT, Consultant - Medical Oncologist in Bhaktivedanta Hospital and Research Institute, Thane, India

DR. JOSE LUIS GARCIA, Senior Medical Strategy Director, Oncology Center of Excellence, IQVIA

DR. CHARU MANAKTALA, Senior Director and Head, Biosimilars Center of Excellence, IQVIA

Acknowledgements

The authors would like to extend their gratitude to Jinu Jose, VP RDS Sales/Clinical Operations, for providing the opportunity to undertake this project. We also wish to thank the following colleagues for their invaluable assistance in organizing the advisory board, which was instrumental in the preparation of this paper:

TANUKA GANGULY, Director, Site & Patient Network, ISS, Local SID

SARANG VINZE, MSc, Associate Director, Patients and Site Services

SHWETA PRADHAN, Director, Clinical Operations

SNEHA PATIL, Senior Admin Assistant

MANISHA KAUSHAL, Senior Site Activation Specialist

TAMALI CHATTERJEE, Senior Site Activation Specialist

SHRUTI GADE, Senior Site Activation Specialist

References

- Mathur, P., Sathishkumar, K., Chaturvedi, M., Das, P., & Stephen, S. (2023). Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India. Indian Journal of Medical Research, 0(0), 0. <u>https://doi.org/10.4103/ijmr.ijmr_1821_22</u>
- 2. Gores, M. (2021). In the Eye of the Storm: PD-(L)1 Inhibitors Weathering Turbulence. In White Paper [White Paper]. <u>https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/iqvia_in-the-eye-of-the-storm_pd-1-inhibitors-weathering-turbulence_05-22-forweb.pdf</u>
- Mandlik, D. S., Mandlik, S. K., & Choudhary, H. B. (2023). Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World Journal of Gastroenterology, 29(6), 1054–1075. <u>https://doi.org/10.3748/wjg.v29.i6.1054</u>
- 4. Global Oncology Trends 2023. (n.d.). IQVIA. <u>https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2023</u>
- Narula, G., Keerthivasagam, S., Jain, H., et. al. (2023). Evaluating the Safety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-CeITM), a Novel Humanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/Refractory B-Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B. Blood, 142(Supplement 1), 6878. <u>https://doi.org/10.1182/blood-2023-180867</u>
- 6. Research, C. F. D. E. A. (2020, August 3). Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. U.S. Food and Drug Administration.
- 7. European Medicines Agency EMA | European Union. (n.d.). European Union. <u>https://european-union.</u> <u>europa.eu/institutions-law-budget/institutions-and-bodies/search-all-eu-institutions-and-bodies/</u> <u>european-medicines-agency-ema_en</u>
- 8. Biosimilars in the United States 2023-2027. (n.d.). IQVIA. <u>https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/biosimilars-in-the-united-states-2023-2027</u>

About the authors



ANJU GOPAN Medical Director, IQVIA

Dr. Anju Gopan has been with IQVIA for over 5 years, serving as a therapeutic medical expert

in medical oncology and hematology. With a career spanning 18 years, she has facilitated oncology advisory boards, presented at webinars and conferences, authored whitepapers, and co-authored articles in oncology. Dr. Gopan is an expert in oncology clinical trials, including the latest evolving oncology therapeutic drugs classes such as CAR T-cells, antibodydrug conjugates, biomarker-driven treatments, and immunotherapy agents. Since 2006, she has served as sub-investigator for multiple international oncology clinical trials and has been a therapeutic medical expert for numerous clinical trials in clinical research organizations for more than 12 years. Dr. Gopan is also a proficient guest speaker in discussions on clinical trials based in India, regulatory issues concerning medical devices, and various oncology panel discussions under both government-sponsored and private programs.



JAIME ENRIQUE HILADO Medical Director, IQVIA

Dr. Jaime Enrique Hilado completed his specialty training in medical oncology last 2013

and served as a sub-investigator in numerous clinical trials in that period. Following his training, he worked in the medical affairs division of a leading global pharmaceutical company in oncology before joining IQVIA 6 years ago. Now, Dr. Hilado serves as a therapeutic medical expert in medical oncology and hematology, conducting advisory boards and committee meetings. Currently, his field of interest includes leukemias, lymphomas, and a wide variety of solid tumors.



DEAN MARVIN PIZARRO

Associate Medical Director, IQVIA

Dr. Dean Marvin Pizarro is a board-certified medical oncologist with 7 years of experience in

clinical practice and research. His areas of expertise include solid epithelial and mesenchymal tumors, as well as hematolymphoid malignancies. He has been a sub-investigator in multiple global oncology clinical trials and currently serves as a therapeutic medical advisor in IQVIA for Asia Pacific and Australia regions. Additionally, he has also published his research papers in local and international peer-reviewed medical journals.

About the authors



JOSE LUIS GARCIA

Senior Medical Strategy Director, Oncology Center of Excellence, IQVIA

José Luis García is senior medical strategy director, Oncology Center of Excellence, at IQVIA. Bringing more than 12 years of clinical oncology experience and nearly two decades in cancer research to his current role at IQVIA, José is currently responsible for overseeing the development of innovative and evidence-driven delivery strategies and solutions for oncology trial programmes, with a specialized focus on brain tumor, liver tumor, gastrointestinal and melanoma studies. Alongside having extensive clinical experience in medical oncology and related patient care, José has served as principal investigator for various clinical and translational phase 1-4 oncology studies and has supported new and expanded existing drug life cycles through his work in medical affairs in the pharmaceutical industry.



CHARU MANAKTALA Senior Director and Head, Biosimilars Center of Excellence, IQVIA

Dr. Charu Manaktala has over

25 years of experience in the healthcare industry, including over 20 years in the pharmaceutical industry. As Senior Director and Head of Biosimilars Centre of Excellence (COE) at IQVIA, she advises biotechnology companies on global and/or region specific clinical and regulatory strategies for the development of biopharmaceutical products, with a special focus on biosimilars. Before joining IQVIA, she held various positions of increasing responsibility at Ranbaxy Laboratories Limited in India.

She has led clinical development pharmaceuticals and biosimilars in a variety of therapeutic areas, with a primary focus on infectious diseases, diabetes, and metabolism.



MARIA ROSELLE LUCAS Senior Medical Director, IQVIA

Dr. Maria Roselle Lucas has more than 20 years of experience in clinical and medical affairs as well

as medical monitoring. A hematologist by profession, she has been involved in numerous hematology and oncology clinical trials. She has provided strategic medical support for product launches and clinical development within IQVIA and in her previous roles. She has also conducted advisory board meetings and leading discussion with key opinion leaders. Her therapeutic expertise includes lymphoproliferative disorders, leukemias, and solid tumors, among others.

CONTACT US

Dr. Anju Gopan India anju.gopan@iqvia.com **iqvia.com**



